Condition: Chronic Kidney Disease and Hypertension · Sponsor: AstraZeneca
International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Surprise, Arizona, United States | Recruiting |
| Research Site | Hollywood, Florida, United States | Recruiting |
| Research Site | Port Charlotte, Florida, United States | Recruiting |
| Research Site | Port Orange, Florida, United States | Recruiting |
| Research Site | Atlanta, Georgia, United States | Recruiting |
| Research Site | Champaign, Illinois, United States | Recruiting |
| Research Site | Wichita, Kansas, United States | Recruiting |
| Research Site | Eatontown, New Jersey, United States | Recruiting |
| Research Site | Greenville, North Carolina, United States | Recruiting |
| Research Site | Jacksonville, North Carolina, United States | Recruiting |
| Research Site | New Bern, North Carolina, United States | Recruiting |
| Research Site | Columbus, Ohio, United States | Recruiting |
+ 59 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07222917